January - March 2012

March 29, 2012		Takeda Announces New Assignment of Directors, Change of Senior Leadership and Reorganization
March 29, 2012		Takeda to Establish a New Global Headquarters Structure to Effectively Align with Expanded Global Operations
March 28, 2012		AFFYMAX AND TAKEDA ANNOUNCE FDA APPROVAL OF OMONTYS® (PEGINESATIDE) INJECTION FOR THE TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE (CKD) IN ADULT PATIENTS ON DIALYSIS
March 26, 2012		Ajinomoto Pharmaceuticals Co., Ltd. and Takeda Submit Application for a Once-Monthly Formulation of Risedronate Sodium Hydrate for the Treatment of Osteoporosis in Japan
March 19, 2012		Presentation of Highlight Results from Phase 3 Trial of TAK-085 in Japan for the Treatment of Hyperlipidemia at the 76th Annual Scientific Meeting of the Japanese Circulation Society
March 13, 2012		Takeda Sets Terms and Conditions for its Domestic Unsecured Straight Bond Issues
March 6, 2012		Millennium Initiates Pivotal Phase 3 Trial of MLN8237 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
February 29, 2012		Takeda to Issue Straight Bonds
February 29, 2012		Leuplin ® 6 Month Depot, Treatment for Prostate Cancer and Premenopausal Breast Cancer Enters into Phase III Clinical Trials in Japan
February 27, 2012		TAKEDA ANNOUNCES ACCEPTANCE OF EUROPEAN MARKETING AUTHORISATION APPLICATION FOR PEGINESATIDE, AN INVESTIGATIONAL COMPOUND FOR THE TREATMENT OF ANEMIA ASSOCIATED WITH CHRONIC KIDNEY DISEASE IN PATIENTS ON DIALYSIS
February 27, 2012		Phase 2 Data of Takeda's Investigational GPR40 Agonist, Published in The Lancet, Demonstrated Improved Glycemic Control in Patients with Type 2 Diabetes
February 21, 2012		Takeda Announces Primary Endpoints Met for Pivotal Phase 3 Trial of VEDOLIZUMAB in Patients with Moderately to Severely Active Ulcerative Colitis Who Have Failed at Least One Conventional Therapy -GEMINI I Trial Met Primary Endpoints of Improvements in Clinical Response in Induction and Clinical Remission in Maintenance-
February 9, 2012		Takeda Announces Establishment of Development Center in China
February 7, 2012		EDARBYCLOR (azilsartan medoxomil and chlorthalidone) Now Available in U.S. Pharmacies for Patients with Hypertension
January 31, 2012		Takeda's Annual Report 2011 and CSR Data Book 2011 Receive Special Prize in Sustainability Reporting Award
January 27, 2012		Anti-Prostate Cancer Agent Orteronel(TAK-700) Enters into Phase III Clinical Trials in Japan
January 24, 2012		FDA Approves Subcutaneous Administration of VELCADE® In All Approved Indications
January 18, 2012		Takeda Announces Strategic Measures to Achieve Efficiencies for Long-Term Growth
January 18, 2012		New Drug Application Approval for AZILVA® in Japan, a Treatment of Hypertension
January 10, 2012		European Commission Adopts European Medicines Agency's Opinion Confirming Pioglitazone-Containing Medicines Remain a Valid Treatment Option for Appropriate Type 2 Diabetes Patients
January 6, 2012		Establishment of Joint Research Chair by Takeda and Osaka University